Ann: ACTION3 IND Approved in China, page-97

Perhaps I can help with your poor research abilities:

1. It actually took 7 months (not 14) to recruit the first 72 patients (as announced 15 Dec 2022)
2. You don't appear to understand the difference between 'recruiting onto the trial' and 'randomising to DXB-200 or placebo'. Better check it out
3. In the first 14 months, 133 had been recruited into the trial, with 72 of these completing the 6-month stabilisation period and randomised and due for completion of the 35-week measurement phase in Feb 2024
4. By July 2023, 61 of the 72 recruits for the 2nd cohort had been recruited and commenced stabilisation - suggesting that the randomisation process for the 2nd group should complete around Feb 2024 - with 35 week measurement phase completing around November 2024.
5. You forgot to mention the all important possibility that the 2nd interim data analysis point - around November 2024 based on current recruitment rates - may enable accelerated marketing approval.

In other words, your analysis is way off the mark!

What is not clear is whether you are just careless or whether you are deliberately spreading misinformation for the purpose of manipulating the share price for your own benefit. I suspect the latter.